GGrantIndex
Sort

64,565 grants matching drug discovery

A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation

$1,024,309
Robert S Langer · Massachusetts Institute Of Technology · R01 · FY2018 · EB

Genomic Studies of the Impact of External Factors on Parasite Development and Disease Outcome

$1,024,222
Joana Carneiro Da Silva · University Of Maryland Baltimore · U19 · FY2019 · AI

Pacific Northwest Advanced Compound Identification Core

$1,024,120
Thomas O Metz · Battelle Pacific Northwest Laboratories · U2C · FY2020 · ES

SBIR Phase II: High-Throughput Specific Cell Loading by Optoinjection

$1,024,000
Glenn Sasaki · Cyntellect, Inc · · FY2003 · TIP

Inhibition of Malaria Chloroquine Resistance Transporters

$1,023,775
M.g. Finn · Scripps Research Institute, The · R56 · FY2010 · AI

Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease

$1,023,733
Jin Wang · Baylor College Of Medicine · U01 · FY2023 · AG

1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Center

$1,023,664
Romonia Renee Reams · Florida Agricultural And Mechanical Univ · U54 · FY2025 · CA

Resource for Structure-based Computational Drug Discovery and Design (RSD3)

$1,023,253
Stefano Forli · Scripps Research Institute, The · R24 · FY2023 · GM

First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development

$1,023,231
Rajesh Krishnan · Oncternal Therapeutics, Inc. · R44 · FY2022 · CA

Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer

$1,023,150
Thirumala-Devi Kanneganti · St. Jude Children'S Research Hospital · R35 · FY2024 · CA

Next generation free energy perturbation (FEP) calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises

$1,022,908
David A Pearlman · Quantum Simulation Technologies, Inc. · R44 · FY2024 · GM

Targeting tau for the development of novel Alzheimer's disease therapeutics

$1,022,579
Glenn Larsen · Aquinnah Pharmaceuticals, Inc. · R44 · FY2021 · AG

Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer

$1,022,522
Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2025 · CA

Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens

$1,022,514
Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2021 · AI

Core B Medicinal Chemistry

$1,022,482
Joel Stephen Freundlich · Hackensack University Medical Center · U19 · FY2019 · AI

Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer

$1,022,419
Stuart H. Yuspa · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Northeast Node of the National Drug Abuse Clinical Trials Network

$1,022,375
Lisa A Marsch · Dartmouth College · UG1 · FY2020 · DA

RNAi Screening in Hematopoietic Cells

$1,022,358
Iain Fraser · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

BIOTECHNOLOGY RESOURCE DIGITAL ELECTROOPTICAL IMAGING

$1,022,246
Cornell University Ithaca · P41 · FY2001 · RR

Novel Small-Molecule Therapies for CF

$1,021,850
Alan S Verkman · University Of California, San Francisco · P30 · FY2016 · DK

Functionally Validated Lentiviral siRNA libraries

$1,021,240
Alex Chenchik · Cellecta, Inc. · R44 · FY2011 · RR

IGF::OT::IGF Medication Discovery Using Rat Models of Relapse; POP 8/29/2014-7/9/2017; FY16 N01DA-14-8917

$1,021,163
Patrick Beardsley · Virginia Commonwealth University · N01 · FY2016 · DA

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs

$1,021,151
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Identification of novel MDR antimicrobials from symbioses between terrestrial and marine invertebrates and rare microbial taxa

$1,020,785
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2020 · AI

DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE

$1,020,676
University Of Florida · P01 · FY2002 · AG